Display options
Cite
Laderas TG, Heiser LM, Sönmez K. A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Front Genet. 2015;6:341doi: 10.3389/fgene.2015.00341.
Laderas, T. G., Heiser, L. M., & Sönmez, K. (2015). A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Frontiers in genetics, 6341. https://doi.org/10.3389/fgene.2015.00341
Laderas, Ted G, et al. "A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity." Frontiers in genetics vol. 6 (2015): 341. doi: https://doi.org/10.3389/fgene.2015.00341
Laderas TG, Heiser LM, Sönmez K. A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Front Genet. 2015 Dec 23;6:341. doi: 10.3389/fgene.2015.00341. eCollection 2015. PMID: 26779250; PMCID: PMC4688377.
Copy Download .nbib Format: NLM
Share it on

Front Genet. 2015 Dec 23;6:341. doi: 10.3389/fgene.2015.00341. eCollection 2015.

A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity.

Frontiers in genetics

Ted G Laderas, Laura M Heiser, Kemal Sönmez

Affiliations

  1. OHSU Knight Cancer Institute, Oregon Health & Science University, PortlandOR, USA; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, PortlandOR, USA.
  2. Department of Biomedical Engineering, Knight Cancer Institute, Oregon Health & Science University, Portland OR, USA.

PMID: 26779250 PMCID: PMC4688377 DOI: 10.3389/fgene.2015.00341

Abstract

Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, invasion, and other cancer hallmarks. The goal of precision medicine is to identify therapeutically-actionable mutations from large-scale omic datasets. However, the multiplicity of oncogenes required for transformation, known as oncogenic collaboration, makes assigning effective treatments difficult. Motivated by this observation, we propose a new type of oncogenic collaboration where mutations in genes that interact with an oncogene may contribute to the oncogene's deleterious potential, a new genomic feature that we term "surrogate oncogenes." Surrogate oncogenes are representatives of these mutated subnetworks that interact with oncogenes. By mapping mutations to a protein-protein interaction network, we determine the significance of the observed distribution using permutation-based methods. For a panel of 38 breast cancer cell lines, we identified a significant number of surrogate oncogenes in known oncogenes such as BRCA1 and ESR1, lending credence to this approach. In addition, using Random Forest Classifiers, we show that these significant surrogate oncogenes predict drug sensitivity for 74 drugs in the breast cancer cell lines with a mean error rate of 30.9%. Additionally, we show that surrogate oncogenes are predictive of survival in patients. The surrogate oncogene framework incorporates unique or rare mutations from a single sample, and therefore has the potential to integrate patient-unique mutations into drug sensitivity predictions, suggesting a new direction in precision medicine and drug development. Additionally, we show the prevalence of significant surrogate oncogenes in multiple cancers from The Cancer Genome Atlas, suggesting that surrogate oncogenes may be a useful genomic feature for guiding pancancer analyses and assigning therapies across many tissue types.

Keywords: breast neoplasms; drug sensitivity; network; oncogenic collaboration; survival

References

  1. Genome Biol. 2013;14(10):R110 - PubMed
  2. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  3. Oncogene. 2010 Sep 16;29(37):5193-203 - PubMed
  4. J Clin Oncol. 2009 Mar 10;27(8):1160-7 - PubMed
  5. Genome Biol. 2012 Dec 22;13(12):R124 - PubMed
  6. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  7. Annu Rev Pathol. 2011;6:49-69 - PubMed
  8. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  9. Nature. 2013 Jul 11;499(7457):214-8 - PubMed
  10. Clin Breast Cancer. 2008 Dec;8 Suppl 4:S157-65 - PubMed
  11. Pac Symp Biocomput. 2012;:55-66 - PubMed
  12. Nature. 2011 Aug 10;476(7359):163-9 - PubMed
  13. Genome Biol. 2011;12(4):R41 - PubMed
  14. Semin Cancer Biol. 2013 Aug;23(4):219-26 - PubMed
  15. Nature. 2012 Mar 28;483(7391):570-5 - PubMed
  16. Cancer Cell. 2006 Dec;10(6):515-27 - PubMed
  17. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  18. Mol Cancer Ther. 2013 Dec;12(12):2950-61 - PubMed
  19. Lancet. 2012 Feb 18;379(9816):633-40 - PubMed
  20. Nat Methods. 2013 Nov;10(11):1108-15 - PubMed
  21. Nat Biotechnol. 2014 Dec;32(12):1202-12 - PubMed
  22. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  23. Genome Res. 2012 Feb;22(2):398-406 - PubMed
  24. Genome Res. 2012 Aug;22(8):1589-98 - PubMed
  25. Curr Protoc Bioinformatics. 2013 Mar;Chapter 8:Unit 8.17 - PubMed
  26. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9 - PubMed

Publication Types

Grant support